Niki BioSolutions, Inc.

What they do

The company, through subsidiaries like Acticule Life Sciences Limited (80% owned) and Aptorum Medical Limited (90% owned), develops novel therapeutics and operates an outpatient medical clinic under the name Talem Medical. It leverages partnerships with contract research organizations and research institutions to advance its pipeline. As of 2025, it has no approved products and generates minimal revenue.

Revenue drivers

• Clinical services — Revenue from the AML Clinic (Talem Medical) provides a small, recurring revenue stream, though total annual revenue was only $431,378 in 2023, indicating the clinic's limited scale.
• Licensing and partnerships — The company may generate future revenue from licensing its drug candidates or entering into collaboration agreements, but no such revenue is evident in recent filings.
• Research grants and collaborations — Potential non-dilutive funding from collaborations with entities like A*STAR could support development, but no specific amounts are disclosed.

Recent performance

Annual revenue declined from $1.5M in 2021 to $431,378 in 2023, while net losses improved from -$25.0M in 2021 to -$1.4M in 2025. Operating cash flow improved from -$14.7M in 2021 to -$1.8M in 2025. As of December 31, 2025, the company had $3.5M cash, total assets of $18.7M, and total liabilities of $4.9M. No revenue figures for 2024 or 2025 were provided in the data.

Strategy

The company is prioritizing cost reduction and disciplined cash management, as evidenced by shrinking losses and operating cash outflows. It continues to invest in its pipeline, particularly through subsidiaries like Acticule and AML. It may also pursue strategic acquisitions or divestitures, as indicated by recent 8-K events involving an acquisition or disposition. The company relies on equity offerings, such as an ATM offering, to fund operations.

Risks

• Cash runway risk — With only $3.5M in cash as of year-end 2025 and ongoing operating losses, the company may need to raise additional capital to fund operations beyond the near term.
• Clinical and regulatory risk — All product candidates are in development; failure to obtain regulatory approvals (e.g., via 505(b)(2) applications) would prevent revenue generation.
• Dependence on subsidiaries and partners — The company relies on partially-owned subsidiaries (e.g., 80% of Acticule, 90% of AML) and external CROs, which could create conflicts or operational delays.
• Limited revenue base — Revenue is minimal and concentrated in a single clinic; there is no diversified revenue stream to cushion against development setbacks.

Outlook

Management expects continued focus on advancing its pipeline while containing costs. The company may seek additional financing and pursue opportunistic transactions, as recent 8-K filings suggest active corporate development. No specific timelines or revenue guidance were provided in the excerpts.